Related Experiment Video
Updated: Jun 2, 2026

The Joint Effect of Social Comparison and Social Distance on Evaluation of Intertemporal Choice Outcomes in Event-related Potential Studies
Published on: August 25, 2023
Through the looking glass: understanding non-inferiority
Jennifer Schumi1, Janet T Wittes
1Statistics Collaborative, Inc, Washington DC 20036, USA. jennifer@statcollab.com
Non-inferiority trials assess if new treatments are not unacceptably worse than existing ones. This paper explores non-inferiority concepts and regulatory perspectives from the European Medicines Agency and US Food and Drug Administration.
Area of Science:
- Clinical Trials Methodology
- Regulatory Science
Background:
- Non-inferiority trials are crucial for evaluating new medical products.
- These trials compare a new product against a well-established standard treatment.
Purpose of the Study:
- To introduce fundamental concepts of non-inferiority trials.
- To discuss regulatory viewpoints on non-inferiority from major health authorities.
Main Methods:
- Conceptual review of non-inferiority trial design.
- Analysis of regulatory guidelines from the European Medicines Agency (EMA) and United States Food and Drug Administration (FDA).
Main Results:
- Defines the core principles and statistical considerations for non-inferiority.
- Highlights key differences and similarities in EMA and FDA approaches to non-inferiority evidence.
Conclusions:
- Understanding non-inferiority is essential for drug development and approval.
- Regulatory alignment and clear guidelines facilitate the evaluation of new medical interventions.
More Related Videos
Related Concept Videos
Sources of Self-Esteem III: Social Comparison
The Looking Glass Self
Self-Evaluation: Self-Enhancement and Self-Verification
Self-Discrepancy Theory
The Sense of Self: Reflected Self-Appraisal and Social Comparison
Self-Discrepancy and Its Effects
